Wu Zhang, Jin Gao, Lin Kang, Qingxia Li, Jing Zhao, Zhiru Li, Shaowei Guo, Guoyan Qi, Jiandi Huang
Journal: Cancer control : journal of the Moffitt Cancer Center 2024;31():10732748241299072
PMID: 39487853
BACKGROUND
Abnormalities in mitochondrial structure or function are closely related to the development of malignant tumors. Mitochondrial metabolic reprogramming provides precursor substances and energy for the vital activities of tumor cells, so that cancer cells can rapidly adapt to the unfavorable environment of hypoxia and nutrient deficiency. Mitochondria can enable tumor cells to gain the ability to proliferate, escape immune responses, and develop drug resistance by altering constitutive junctions, oxidative phosphorylation, oxidative stress, and mitochondrial subcellular relocalization. This greatly reduces the rate of effective clinical control of tumors.
PURPOSE
Explore the major role of mitochondria in cancer, as well as targeted mitochondrial therapies and mitochondria-associated markers.
CONCLUSIONS
This review provides a comprehensive analysis of the various aspects of mitochondrial aberrations and addresses drugs that target mitochondrial therapy, providing a basis for clinical mitochondria-targeted anti-tumor therapy.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.